Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Wiley
2023-10-01
|
| Seria: | Cancer Medicine |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1002/cam4.6548 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|